Please login to the form below

Not currently logged in
Email:
Password:

Vertex poaches new finance chief from Ironwood Pharmaceuticals

Boston-based biotech company appoints Tom Graney

Vertex Tom GraneyVertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer.

He will join the Boston-based biotech firm next week, when he will be responsible for the development and execution of Vertex’s financial strategy and operations.

Graney will report to Vertex’s chief operating office Ian Smith, who said: “As Vertex continues its evolution to a leading global biotech, it is critical that we continue to build a strong and experienced leadership team.

“Tom has the ideal blend of financial acumen, leadership skills, and industry experience that will be important as Vertex grows and expands as a global company."

Graney most recently spent three years at Ironwood Pharmaceuticals, overseeing its Finance, Corporate Strategy, Corporate Development, Quality, Supply Chain, IT, Corporate Communications and Investor Relations functions.

Prior to that he served at Johnson & Johnson for 20 years in the US and abroad, rising to worldwide VP of finance and CFO for its Ethicon Surgical Care business.

At Ironwood Pharmaceuticals Graney’s replacement as interim chief financial officer will be Gina Consylman, who currently serves as the Cambridge, Massachusetts firm’s VP of finance and chief accounting officer.

8th September 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...